A decision model found sleeve gastrectomy tripled kidney transplant access compared to single GLP-1 drugs, but dual GLP-1/GIP agonists offered a substantial non-surgical alternative.
14.74% vs. 4.83%At 5 years, sleeve gastrectomy got roughly three times as many morbidly obese kidney failure patients to transplant compared to single GLP-1 receptor agonists.
What the researchers found
Using a Markov decision model, researchers compared three weight loss strategies for morbidly obese patients with end-stage kidney disease who need to reach BMI ≤35 to qualify for kidney transplant. At 5 years, sleeve gastrectomy got the most patients to transplant (14.74%), followed by dual GLP-1/GIP receptor agonists like tirzepatide (9.06%), and single GLP-1 agonists (4.83%).
Sleeve gastrectomy produced faster weight loss, with 27.49% of patients reaching the BMI target by 6 months. Surgery also showed a survival advantage, especially in patients starting at higher BMIs.
However, dual GLP-1/GIP agonists still got a substantial number of patients to transplant and represent a viable non-surgical alternative, particularly for patients who cannot undergo or prefer to avoid surgery.
Why it matters
Obese patients with kidney failure face a cruel catch-22: they need a transplant to survive, but many transplant programs require BMI below 35 first. This study quantifies how different weight loss strategies affect the odds of actually reaching that threshold and getting a kidney. It shows surgery is fastest, but the newer dual-agonist drugs offer a meaningful pharmaceutical alternative — especially important for patients too sick for elective surgery.
The numbers in context
14.74% transplant rate with surgery at 5 years · 9.06% with dual GLP-1/GIP agonist · 4.83% with single GLP-1 agonist · 27.49% reached BMI ≤35 by 6 months with surgery
How the study worked
Markov state transition model simulating outcomes for morbidly obese patients with end-stage renal disease under three weight loss interventions. Patients transitioned between health states based on weight loss trajectories, transplant eligibility (BMI ≤35 kg/m²), and survival. Model parameters were derived from published literature on each intervention.
Who was studied
Modeled population of morbidly obese adults with end-stage renal disease seeking kidney transplant eligibility
What this study cannot tell us
This is a mathematical model, not a clinical trial — results depend entirely on the assumptions and input parameters used. Real-world outcomes may differ due to patient adherence, complications, drug availability, and individual variation in weight loss response. The model does not account for weight regain after initial loss or complications specific to dialysis patients undergoing surgery.
How to read the evidence
This is a Markov decision analysis — a mathematical model — not a clinical trial. While useful for comparing strategies, its conclusions depend on assumed parameters from published literature and cannot account for real-world complexity. Evidence certainty is low to moderate.
When this study was published
Published in 2025, this study reflects the current treatment landscape including newer dual GLP-1/GIP agonists. Highly relevant as these drugs become more widely prescribed for obese patients with comorbidities.
The bigger picture
This study sits at the intersection of two major trends — the explosion of GLP-1-based weight loss drugs and the growing recognition that obesity is a barrier to life-saving organ transplants. As dual and triple agonist drugs become available, they may increasingly compete with bariatric surgery as a pathway to transplant eligibility, especially for patients who are poor surgical candidates.
Questions still open
- Would triple agonists (GLP-1/GIP/glucagon) close the gap with surgery even further?
- How does weight regain after stopping GLP-1 drugs affect long-term transplant eligibility?
- Should transplant programs lower their BMI thresholds given effective pharmacological weight loss options?
Common questions
Why can't obese patients get a kidney transplant?
Can GLP-1 drugs replace surgery for getting patients to transplant?
Read the original research
Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to improve access to kidney transplantation in patients with end-stage renal disease and obesity: A decision analysis.
American journal of surgery, 250, 116475
Citation
Di Napoli, Marissa; Rouhi, Armaun D; Baimas-George, Maria; Dumon, Kristoffel; Castle, Rose; Kennealey, Peter; Nydam, Trevor; Choudhury, Rashikh. (2025). Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to improve access to kidney transplantation in patients with end-stage renal disease and obesity: A decision analysis.. American journal of surgery, 250, 116475. https://doi.org/10.1016/j.amjsurg.2025.116475